Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma

Rationale: Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents.Objectives: To determine the association between type 2–related comorbidities and biologic agent effectiveness in adults with severe asthma (SA).Methods: This cohort study used International Severe Asthma Registry data from 21 countries (2017–2022) to quantify changes in four outcomes before and after biologic therapy—annual asthma exacerbation rate, FEV1% predicted, asthma control, and long-term oral corticosteroid daily dose—in patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema/atopic dermatitis.Measurements and Main Results: Of 1,765 patients, 1,257, 421, and 87 initiated anti–IL-5/5 receptor, anti-IgE, and anti–IL-4/13 therapies, respectively. In general, pre- versus post–biologic therapy improvements were noted in all four asthma outcomes assessed, irrespective of comorbidity status. However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10–35%; P < 0.001) and had 59% higher odds of better post–biologic therapy asthma control (95% CI, 26–102%; P < 0.001) than those without CRS with or without NPs. Similar estimates were noted for those with comorbid NPs: 22% fewer exacerbations and 56% higher odds of better post–biologic therapy control. Patients with SA and CRS with or without NPs had an additional FEV1% predicted improvement of 3.2% (95% CI, 1.0–5.3; P = 0.004), a trend that was also noted in those with comorbid NPs. The presence of allergic rhinitis or atopic dermatitis was not associated with post–biologic therapy effect for any outcome assessed.Conclusions: These findings highlight the importance of systematic comorbidity evaluation. The presence of CRS with or without NPs or NPs alone may be considered a predictor of the effectiveness of biologic agents in patients with SA.